Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinoma: a phase II multicenter trial (Q43732866)

26 November 2017

title

Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinoma: a phase II multicenter trial (English)

1 reference

26 November 2017

main subject

phase II clinical trial

0 references

1 reference

V Hirsh

1

1 reference

26 November 2017

A Langleben

2

1 reference

26 November 2017

J Ayoub

3

1 reference

26 November 2017

Y Cormier

4

1 reference

26 November 2017

J Pintos

5

1 reference

26 November 2017

J L Iglésias

6

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

26 November 2017

1 reference

26 November 2017

volume

92

1 reference

26 November 2017

issue

4

1 reference

26 November 2017

page(s)

830-835

1 reference

New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010815%2992%3A4%3C830%3A%3AAID-CNCR1389%3E3.0.CO%3B2-C

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010815%2992%3A4%3C830%3A%3AAID-CNCR1389%3E3.0.CO%3B2-C

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010815%2992%3A4%3C830%3A%3AAID-CNCR1389%3E3.0.CO%3B2-C

Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010815%2992%3A4%3C830%3A%3AAID-CNCR1389%3E3.0.CO%3B2-C

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010815%2992%3A4%3C830%3A%3AAID-CNCR1389%3E3.0.CO%3B2-C

Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010815%2992%3A4%3C830%3A%3AAID-CNCR1389%3E3.0.CO%3B2-C

Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010815%2992%3A4%3C830%3A%3AAID-CNCR1389%3E3.0.CO%3B2-C

Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010815%2992%3A4%3C830%3A%3AAID-CNCR1389%3E3.0.CO%3B2-C

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010815%2992%3A4%3C830%3A%3AAID-CNCR1389%3E3.0.CO%3B2-C

A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010815%2992%3A4%3C830%3A%3AAID-CNCR1389%3E3.0.CO%3B2-C

10.1002/1097-0142(20010815)92:4<830::AID-CNCR1389>3.0.CO;2-C

21 January 2018

Identifiers

DOI

1 reference

26 November 2017

1 reference